Share on LinkedInShare on LinkedIn

ARTICLE · 12 MARCH 2020

March Issue Of Bio/Pharma Beat Now Available!

Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions.

United StatesIntellectual Property

Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month's issue covers relevant news from February 2020, including:

  • A Federal Circuit decision applies a presumption that an express license to a patent includes an implied license to its continuations.
  • A district court finds after trial that defendants' obviousness theory had "major defects and does not come close to meeting the clear and convincing standard."
  • A district court holds that dedication-disclaimer does not apply where the allegedly dedicated subject matter is found in another claim in the same patent.
  • The FDA and FTC announce a collaboration "to advance competition in the biologic marketplace."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from